Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Shares of Mereo BioPharma (NASDAQ:MREO) rose 7% Friday after Jefferies initiated coverage of the stock with a buy rating, citing the company’s drug candidates setrusumab and alvelestat.

Ultragenyx’s recent meeting focused on setrusumab and the ongoing Phase 3 ORBIT trial. The analyst noted that the company remains confident in the trial’s success, with a second interim ...

“Based on the highly promising data from completed studies of setrusumab in OI, including the Phase 2 portion of the Orbit Study, we remain confident in the potential of setrusumab to become the ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung ...

The company also provided key program updates including that the UX143 (setrusumab) Phase 3 Orbit study is progressing with the second interim analysis in mid-2025. “In 2024 we grew our business ...

The Phase 3 portion of the pivotal Phase 2/3 Orbit study is evaluating the effect of setrusumab compared to placebo on clinical fracture rate in patients aged five to under 26. The newly initiated ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung ...

Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final ...